Audited Supplier
100ml
Surgery
Elderly, Children, Adult
Liquid
Inorganic Chemicals
Chemical Synthesis
H20020463
Huaren
Carton
100ml
China
Product Description
Drug name :Isosorbide Mononitrate Sodium Chloride Injection
Character:This product is colorless clear liquid
Indications:
It is suitable for the treatment of angina pectoris and the treatment of chronic heart failure in combination with digitalis and/or diuretics.
Specification:
| Isosorbide Mononitrate Sodium Chloride Injection | 100ml:Isosorbide mononitrate 20mg Sodium Chloride 0.9g | Non PVC soft bags |
Founded in May 1998, Huaren Pharmaceutical is a modern pharmaceutical and health industry group integrating R&D, production and sales, focusing on medicine, health, medical equipment and medical services.
In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, the stock abbreviation is "Huaren Pharmaceutical", stock code "300110". In July 2019, the company underwent a change of shareholding, and the management committee of Xi'an Qujiang New Area became the actual controller of the company.
After more than 20 years of development, the company's business focuses on nephrology, respiratory, fine hemp and large-volume preparations and other fields, and has successively built five production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags (bottles), and all production lines have passed the new GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, health products and APIs, etc., with a total of 98 varieties and 212 specifications of existing drugs, realizing the integrated development of "raw materials + preparations + pharmaceutical packaging materials".
In August 2010, the company was successfully listed on the Shenzhen Stock Exchange, the stock abbreviation is "Huaren Pharmaceutical", stock code "300110". In July 2019, the company underwent a change of shareholding, and the management committee of Xi'an Qujiang New Area became the actual controller of the company.
After more than 20 years of development, the company's business focuses on nephrology, respiratory, fine hemp and large-volume preparations and other fields, and has successively built five production bases in Qingdao, Rizhao, Xiaogan, Pubei and Hefei, with a total production capacity of 950 million bags (bottles), and all production lines have passed the new GMP certification. The company's main products include small-volume injections, peritoneal dialysate, therapeutic infusions, basic infusions, medical devices, tablets, capsules, powders, granules, supporting drug packaging, health products and APIs, etc., with a total of 98 varieties and 212 specifications of existing drugs, realizing the integrated development of "raw materials + preparations + pharmaceutical packaging materials".
Pharmaceutical packaging materials,Rubber stoppers and APIs are self-produced and self-sold, the price is lower and the quality is more guaranteed.
